BTSG vs GMAB: fair value comparison
BrightSpring Health Services, Inc. and Genmab A/S · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, BTSG currently sits closer to the top of our discount ranking. GMAB carries the stronger quality grade.
| BTSG | GMAB | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $60.47 | $28.68 |
| 12-month range | $23.88–$69.85 | $25.45–$33.27 |
| Sector rank | #44 of 113 Healthcare | #45 of 113 Healthcare |
| Quality grade | D | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: BTSG fair value analysis · GMAB fair value analysis